We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
VKORC1 and CYP2C9 polymorphisms are associated with warfarin dose requirements in Turkish patients.
- Authors
Oner Ozgon, G.; Langaee, T. Y.; Feng, H.; Buyru, N.; Ulutin, T.; Hatemi, A. C.; Siva, A.; Saip, S.; Johnson, J. A.
- Abstract
The objective of this study was to determine the quantitative influence of vitamin K epoxide reductase complex subunit 1 ( VKORC1) and cytochrome P450 2C9 ( CYP 2C9) polymorphisms on warfarin dose requirements in Turkish patients. A total of 205 patients taking warfarin for >2 months were enrolled in the study. Deoxyribonucleic acid (DNA) samples from these patients were genotyped for polymorphisms in VKORC1 and CYP2C9 genes. A linear regression analysis was used to determine the independent effects of genetic and non-genetic factors on mean warfarin dose requirements. The VKORC1 promoter polymorphism (3673 G>A) was associated with differences in weekly mean varfarin dose: for GG genotype the dose was 43.18 mg/week, for GA genotype 33.78 mg/week and for AA genoype 25.83 mg/week ( P < 0.0001). Patients who carried VKORC1 and CYP2C9 variants needed a 40% lower mean weekly warfarin dose compared to wild types. Variables associated with lower warfarin dose requirements were VKORC1 3673 AA or GA genotype (both P < 0.0001), one or two CYP2C9 variant alleles (both P < 0.0001), increasing age ( P < 0.0001) and non-indication of venous thromboembolism for warfarin therapy ( P = 0.002). Polymorphisms in VKORC1 and CYP2C9 genes were important determinants of warfarin dose requirements in Turkish patients.
- Subjects
VITAMIN K; ISOPENTENOIDS; CYTOCHROME P-450; CYTOCHROMES; WARFARIN; DNA; REGRESSION analysis; DRUG dosage; THROMBOEMBOLISM
- Publication
European Journal of Clinical Pharmacology, 2008, Vol 64, Issue 9, p889
- ISSN
0031-6970
- Publication type
Article
- DOI
10.1007/s00228-008-0507-5